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Abstract: The microbiome plays an important role in a wide variety of skin disorders. Not only is
the skin microbiome altered, but also surprisingly many skin diseases are accompanied by an altered
gut microbiome. The microbiome is a key regulator for the immune system, as it aims to maintain
homeostasis by communicating with tissues and organs in a bidirectional manner. Hence, dysbiosis
in the skin and/or gut microbiome is associated with an altered immune response, promoting the
development of skin diseases, such as atopic dermatitis, psoriasis, acne vulgaris, dandruff, and even
skin cancer. Here, we focus on the associations between the microbiome, diet, metabolites, and immune
responses in skin pathologies. This review describes an exhaustive list of common skin conditions with
associated dysbiosis in the skin microbiome as well as the current body of evidence on gut microbiome
dysbiosis, dietary links, and their interplay with skin conditions. An enhanced understanding of the
local skin and gut microbiome including the underlying mechanisms is necessary to shed light on the
microbial involvement in human skin diseases and to develop new therapeutic approaches.
Keywords: skin microbiome; gut dysbiosis; atopic dermatitis; acne vulgaris; psoriasis; dandruff; skin
cancer; rosacea; wound healing; dietary; probiotics
1. Introduction
The skin epidermis, along with its appendage structures, such as sweat and sebaceous
glands, provide a total skin surface of about 25 m2 and is one of the largest epithelial
surfaces for interaction with microbes [1]. The skin is a first-line barrier from the outer
environment, continuously interacting with it. The gastrointestinal (GI) tract is one of
the largest interfaces (30 m2) between the host and its environment [2]. About 60 tons of
food is estimated to pass through the gut in a lifetime, all of which have a big impact on
human health [3]. Both the gut and skin are immensely immersed with microbiota as it
is estimated that the skin has about 1012 microbial cells while the gut accounts for 1014
microbial cells [4,5]. The microbiota point to the assemblage of specific microorganisms that
are present within a defined environment. The emergence of next-generation sequencing
in the past decade has provided unprecedented insights into microbiome composition,
both on skin and in the gut. The microbiome refers to the genomes present in a certain
environment, meaning the accumulation of all their genetic material (i.e., DNA and RNA).
Both organs are characterized by a low microbial diversity at the phylum level but high
diversity at the species level [6]. The microbiome provides a multitude of benefits to the
host, such as shaping the immune system, protecting against pathogens, breaking down
metabolites, and maintaining a healthy barrier [3].
The immuno-modulating potential of the microbiome on distant organ sites is an
expanding research field. Especially the influence of the gut microbiome on distant organs,
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such as the lung, brain, and skin, have created the following areas of research: gut–lung
axis, gut–brain axis, and gut–skin axis [7]. The innate and adaptive immune systems alter
the microbial composition; however, the local microbiome can also modulate the immune
system. The underlying mechanisms of how the gut microbiome alters the skin’s immune
system, and vice versa, are currently being investigated. Several skin pathologies pose
as gut comorbidities. Several studies have demonstrated the bidirectional link between
gut dysbiosis and skin homeostasis imbalances, with a particular role of gut microbiota
dysbiosis in the pathophysiology of multiple inflammatory diseases [8–10].
A summary of recent findings in the skin and gut microbiome in multiple skin dis-
orders is given in this review, highlighting some potential mechanisms underlying the
gut–skin axis.
2. Skin Versus Gut Barrier
The gut and skin barrier share surprisingly many features. The gut and skin are highly
analogous to each other in purpose and functionality. Both organs are highly innervated
and vascularized, as they are both essential for immune and neuroendocrine function [11].
The gut–skin axis results from this resemblance [11]. The inner surface of the gut and the
outer surface of the skin are both covered by epithelial cells (ECs) which have direct contact
with the exogenous environment [12]. This way, the immune system is continuously primed
to distinguish between harmful and beneficial compounds. Immune cell priming starts
early on in life and forms the basis of tolerance, a crucial concept hypothesized to be flawed
in several autoimmune disorders [13]. ECs maintain an important link between the internal
body and the external environment. They act as a first line of defense, preventing the entry
of microorganisms [12]. Keratin, which is present in the stratified squamous epithelium of
the skin, presents a formidable physical barrier to most microorganisms [14]. In addition,
this compound makes the skin resistant to weak acids and bases, bacterial enzymes,
and toxins [15]. Mucosae provide similar mechanical barriers, as it comprises a glycoprotein
layer on top of the epithelium in which commensal bacteria reside [16,17]. The epithelial
membranes produce protective chemicals that eliminate microorganisms [18]. The skin
acidity (pH of 5.4 to 5.9) creates an inhospitable environment for potential pathogens and
inhibits bacterial growth [19]. Sebum produced by the sebaceous glands acts as a seal for
hair follicles and contains several antimicrobial molecules as well as specific nutritional
lipids for beneficial microorganisms [20,21]. Meanwhile, in the digestive system, saliva
and lacrimal fluid contain lysozyme, followed by the stomach mucosae that secrete strong
acid and protein-digesting enzymes [22]. In addition, mucus traps microorganisms that
enter the digestive and respiratory tract [23].
The second line of defense are the antimicrobial peptides (AMPs), phagocytes, and in-
nate lymphoid cells (ILCs) [24]. These two first lines of defense form the innate immune
system [23]. AMPs produced by keratinocytes, such as cathelicidin and psorasin, provide
an effective barrier function to the skin [25,26]. The serine protease Kallikrein 5 (KLK5)
cleaves cathelicidin into active peptides, such as LL-37 [27]. Compared to the skin, the com-
position of the intestinal epithelial barrier varies throughout the gastrointestinal tract. The
proximal part of the gastrointestinal tract, the mouth and esophagus, is analogous to the
skin, covered by multiple layers of squamous epithelium, which is cleansed by mucus
from salivary and other glands [28]. The remaining part of the digestive tract includes
a single layer of active cells, e.g., goblet cells (mucus secretion), enteroendocrine cells
(hormone secretion), enterocytes or colonocytes (absorption), etc. [29,30]. The intestinal
epithelium constitutes a single layer of enterocytes or colonocytes, and its barrier integrity
is protected by the immune system. The absorptive functionality of the enterocytes in the
small intestine ensues a discontinuous layer of mucus with fewer goblet cells [31]. Paneth
cells are enriched in the crypts of the small intestine that secrete AMPs, which integrate in
the complex mucus layer [32].
Microbial-associated molecular patterns (MAMPs) are sampled through antigen up-
take by membranous (M) cells and goblet cells to dendritic cells (DCs), together with direct
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transepithelial luminal DCs. Microbial signals are sensed by RORγt innate lymphoid Cclls
(group 3 ILCs) that produce interleukin-17 (IL-17) and IL-22 [33]. The latter acts directly
on the intestinal epithelial cells (IECs) and activates damage repair mechanisms, AMPs,
and mucin genes [34]. Plasma cells in Peyer’s patches, which are stimulated by DCs, pro-
duce IgA in the lamina propria in a T cell-independent manner [35,36]. The large intestine
on the other hand contains a thick, continuous mucus layer to compartmentalize the mi-
crobiota, with IgA and AMPs having a secondary role [17]. The control of immunological
processes within mucosal tissues is dependent on the interaction between ECs and DCs,
as both cell types are involved in the sensing and sampling of antigens [12]. In the skin
and intestine, pathogens are sampled via M cell-independent mechanisms [37]. The only
DCs that are found within the epidermis are the Langerhans cells (LCs) [12].
Other similarities between the gut and skin tissues is the high cellular turnover rate,
which inhibits adherence and infection by the colonizing microbiome [38,39]. The skin and
the gut are the two major niches that host prokaryotic and eukaryotic symbiotic microorgan-
isms [40,41]. However, the resident microbiota are frequently involved and play a crucial role
in the pathogenesis of several diseases [42]. Both tissues are very responsive to stress and
anxiety, as they face similar challenges. Remarkably, diseases such as inflammatory bowel
Disease (IBD) and psoriasis comprise an epithelial barrier dysfunction and an increased ep-
ithelial cellular turnover rate. The increased permeability of the epidermal skin and intestinal
barrier is due to the augmented interaction of allergens and pathogens with inflammatory
receptors of immune cells. Both diseases have an analogous immune response and involve
phagocytic, dendritic, and natural killer cells along with a range of cytokines and AMPs that
induce a T cell response [43]. In addition, both diseases are characterized by dysbiosis in the
microbiome composition that covers the respective interface linings [43].
The gut microbiome is the largest endocrine organ, producing at least 30 hormone-like
compounds, e.g., short chain fatty acids (SCFAs); secondary bile acids; cortisol; and neu-
rotransmitters such as gamma-aminobutyric acid (GABA), serotonin, dopamin, and tryp-
tophan. Certain members of the gut microbiome respond to hormones secreted by the
host [44]. The hormone-like pleiotropic compounds that are produced by the gut mi-
crobiome are released into the bloodstream and can act at distant organs and systems,
such as the skin [44]. Numerous studies provided evidence for a profound bidirectional
link between gastrointestinal health and skin homeostasis through modification of the
immune system [45–47]. Modulation of the immune system occurs primarily through the
gut microbiota. However, commensal skin microbiota are evenly essential for maintenance
of the skin immune homeostasis [48]. Both the intestine and the skin host diverse bacterial,
fungal, and viral species that maintain symbiosis with the human habitat. Disrupting
this balance might lead to an impaired barrier function. Skin homeostasis recovery after
disturbance or stress through gut microbiota enacts on both innate and adaptive immunity.
3. Skin and Gut Microbiome Involvements
The skin is the largest and most external barrier of the body with the outer environ-
ment. It is richly perfused with immune cells and heavily colonized by microbial cells,
which in turn train the immune cells and determine the well-being of the host [49]. The skin
microbiome has gained significant attention in recent years in dermatology, skin disorders,
and its connection and influence on the immune system. Many skin conditions are asso-
ciated with an imbalance in the skin microbiome (Table 1). More and more studies have
shown enriched pathogens and microbiota that are associated with skin conditions, some
of which are obvious and others more surprising. It is nonetheless difficult to determine
whether the altered skin microbiome is a cause or consequence of the skin disorder.
The intestinal tract harbors a diverse collection of bacteria, fungi, and protozoa [50].
Many of these microorganisms are essential for metabolic and immune function, as they
metabolize indigestible complex polysaccharides into essential nutrients such as vitamin K
and B12, butyrate, and propionate [51,52]. The latter have a positive effect on the epithelial
barrier integrity. Intestinal barrier integrity plays a crucial role in protecting microbiota from
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entering the systemic circulation and in avoiding inflammation in the gut. Diet can have a
vital role in the maintenance of particular skin pathologies, when those food ingredients
impair the intestinal barrier, which leads to gut bacteria entering the bloodstream.
Lifestyle factors such as diet and hygiene have a determining impact on the tolerance
of the immune system to commensal microbiota, which in combination with genetic
susceptibility, leads to microbial dysbiosis and disease. For instance, a Western diet has
been associated with the development of numerous immune-mediated inflammatory
diseases (IMIDs), such as rheumatoid arthritis, psoriasis, and atopic dermatitis (AD).
Similarly, the hygiene hypothesis has been linked to the development of Th2-mediated
diseases such as asthma and atopic dermatitis. The hygiene hypothesis implies that a
reduced exposure to microbes through modern health practices can lead to increased
inflammatory diseases in the urbanized society [53]. An overly hygienic lifestyle prevents
microbial stimulation and can cause an atopic Th2-skewed response. People living in
non-urbanized environments (indigenous people and farming environments) are usually
not characterized by inflammatory diseases [54,55]. The mechanism of the Western diet,
or high-fat diet (HFD) relies on the resulting intestinal dysbiosis, leading to an increase in
the ratio of Firmicutes to Bacteroidetes. The mechanism for this phenomenon is outlined
by Guo et al., who found that, in mice, HFD leads to a decreased release of AMPs in the
small intestine, which is followed by changes in the composition of the gut microbiota
and subsequent alterations in serological inflammatory cytokine levels [56].
Other nutritional components such as glycoalkaloids, alpha tomatine, and capsaicin,
which are characteristic for the nightshade family legumes, have been associated with
intestinal permeability [57]. In a similar manner, gluten can have an impact on skin health.
Coeliac disease and gluten sensitivity have been linked with several skin conditions [58].
Dermatitis herpetiformis is a cutaneous manifestation of celiac disease, and patients can
clear up skin rashes when shifting to a gluten-free diet for several months up to several
years. The rashes generally return when patients resume gluten consumption [59]. Other
allergic and autoimmune diseases, including psoriasis, have been associated with gluten
intolerance [58]. Similarly, the strong association between atopic dermatitis and food
allergy demonstrates the importance of food underlying the gut–skin axis [60].
However, the gut–skin axis not only is governed by diet but also acts bidirectionally.
Skin exposure to ultraviolet B (UVB) and therefore indirectly to serum vitamin D levels
increase the α and β diversity of the gut microbiome [61]. Bacteria from several families
were enriched, and the serum vitamin D levels were correlated with the relative abundance
of Lachnospira and Fusicatenibacter genera [61]. Moreover, food allergies may result from an
impaired skin barrier: atopic dermatitis sensitizes to peanut allergy due to epicutaneous
peanut protein exposure in household dust, leading ultimately to immunoglobulin E (IgE)-
mediated mast cell expansion in the gut [62,63]. More specifically, the duodenum and
oesophagus act as reservoirs for IgE+ B lineage cells [64].
Dysbiosis in the gastrointestinal system is quite often linked to inflammatory diseases
(Table 2) [8–10]. Gastrointestinal disorders are associated with certain dermatoses, for in-
stance, 7–11% of patients with IBD also suffer from psoriasis [65]. The connection between
the skin and gut seems to be mediated by the host immune system. The interaction of the
microorganisms and the host immune system is important to maintain the skin homeostasis.
The gut–skin axis may be viewed as an integral part of the gut–brain–skin axis, elegantly
described by Arck et al. and by Bowe and Logan [7,66]. Table 3 lists neurotransmitters
that are produced by intestinal microbiota that might cross the intestinal barrier, enter the
bloodstream, and instigate systemic effects (Figure 1) [67,68]. In addition, SCFAs, such
as butyrate, acetate, and propionate, are fermentation products derived from undigested
polysaccharides by intestinal bacteria (e.g., Bacteroides, Bifidobacterium, Cutibacterium, Eu-
bacterium, Lactobacillus, and Prevotella) [69]. These SCFAs, especially butyrate, enhance
epithelial barrier function and decrease the permeability of the intestinal barrier [70]. How-
ever, the SCFA quantity that enters the bloodstream is dependent on the individual fiber
intake, the microbial fermentation rate, and the amount of colon absorption. All these
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compounds, which are derived from the gut, could all interact with skin receptors and
could directly affect the skin or modify the skin’s commensal bacteria. Further research is
needed to reveal if a clinical significant amount of SCFAs is reached in the bloodstream to
affect the skin [11]. The studies from Table 3 support that the gut and skin interact with one
another via the diet, microbial metabolites, the neuroendocrine pathways, and the central
nervous system.
Here, we provide an overview of nine common skin disorders and their respective
pathophysiology, and the body of knowledge regarding their skin microbiome alterations,
imbalanced gut microbiome, and/or relation to a specific diet.
Table 1. Skin microbiota associated with nine common skin disorders.
Disease Associated Skin Microbiota Additional Remarks Reference





Herpes simplex virus and coxsackie





Anti-psoriasis treatments lead to





Anaerobic species in lesions. [89,90]
5. Rosacea Demodex folliculorum (mites)
C. acnes decreased and Snodgrassella









Potential role of cytomegalovirus





Increase in certain strains of
S. aureus in combination with a
decrease in skin commensals can be
associated to SCC * or BCC *, and
that in MCPyV * can be associated
to MCC *.
[100–103]
9. Wound healing S. aureus andbiofilm-forming bacteria.
Lactobacilli and fermented
products can be beneficial. [104,105]
* Abbreviations: atopic dermatitis (AD), basal cell carcinoma (BCC), hidradenitis suppurativa (HS), Merkel cell carcinoma (MCC),
Merkel cell Polyomavirus (MCPyV), and squamous cell carcinoma (SCC).
Table 2. Gut microbiota associated with nine common skin disorders.
Disease Associated Gut Microbiota Additional Remarks Reference
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Table 2. Cont.




Clostridium, and Escherichia (in




prevent AD *. [107–114]
3. Psoriasis
Changes in β-diversity. Gut
microbiome changes in
reaction to biologicals.
Increased risk of intestinal immune
disorders. Diet and gut microbiome
can have an impact on
inflammation.
[115–120]
4. Hidradenitis suppurativa Unknown Increased risk in developing CD *and UC *. [121,122]
5. Rosacea









Probiotic consumption can alleviate
moderate to severe dandruff [126]
7. Alopecia areata No major differences FMT * in 2 patients showedrestoration of hair growth [127,128]
8. Skin cancer Not reported Other cancers are associated withmicrobial dysbiosis [129–131]
9. Wound healing Not reported Not reported
* Abbreviations: atopic dermatitis (AD), Crohn’s disease (CD), fecal microbiota transplant (FMT), hidradenitis suppurativa (HS),
small intestinal bacterial overgrowth (SIBO), and ulcerative colitis (UC).
Table 3. Molecules with potential a modulatory effect on skin and gut either directly or indirectly.
Molecule Documented/Possible effectin gut Documented/Possible effect on skin Reference
Bacterial metabolites
SCFAs * Anti-inflammatory effects Anti-inflammatory effects [132]
Vitamin D Suppress inflammation in IBD* Not reported [133]
Urocanic Acid Suppress inflammation in IBD* Not reported [134]
GABA * Neurotransmitter modulation Itch restriction [135,136]
Dopamine Neurotransmitter modulation Inhibition of hair growth [135,137]
Serotonin Neurotransmitter modulation Melatonin modulation [135,138]
Acetylcholine Neurotransmitter modulation Barrier function [135,139]
Phenol and p-cresol Biomarker of gut dysbiosis Impaired epidermal barrier function [140]
Dietary components
Catechins Anti-inflammatory effects Anti-inflammatory effects [141]
Polyphenols Anti-inflammatory effects Anti-inflammatory effects [142]
Lycopene Selectively utilized byhost microbiota Protection against photodamage [143,144]
Prolamin Not reported Protection against AD * [145]
Phytomolecules Not reported Anti-ageing [146]
Gluten Coeliac disease Skin Rashes [58,59]
* Abbreviations: atopic dermatitis (AD), gamma-aminobutyric acid (GABA), inflammatory bowel disease (IBD), and short chain fatty
acids (SCFAs).
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4. Acne Vulgaris
4.1. Acne Vulgaris Pathophysiology
Acne vulgaris is a multifactorial disease with the main drivers being the skin micro-
biome composition, the hormonal and immunological state of the host, sebum production,
diet, FoxO1 deficiency, hormonal disorders, and deregulation of insulin-like growth factor.
Acne vulgaris is the most common skin disorder in the Western world; it can affect 79% or
95% of the Western adolescent population [147]. It is surprisingly absent in hunter–gatherer
communities and communities that live a traditional, non-Western lifestyle [147]. The im-
munology contribution is shaped by the innate immunity, adaptive immunity, and the T
helper 17 (Th17) pathway [148,149]. However, the clinical relevance of the Th17 pathway in
this disease still has to be evaluated as CD4+ IL-17-producing T cells were also found next
to non-inflamed sebaceous glands [150,151]. A very different axis in the development of
acne vulgaris is the insulin levels and insulin-like growth factor (IGF) concentrations. Some
studies reported that IGF deficiency can protect from acne vulgaris [152]. A more compli-
cated interplay with diet and other drivers in acne vulgaris is likely [153,154]. Currently,
the main therapeutic approach includes antibacterial compounds, retinoids, or comedolytic
actives. The diversity in mode of actions make it obvious that the underlying disease has
many contributors [155].
4.2. Acne Vulgaris Skin Microbiome
Acne vulgaris is a widespread skin disease that usually affects sebaceous skin areas.
The pathology and associated skin microbiome dysbiosis has been linked with certain strains
of Cutibacterium acnes. The suggested factors range from sebum induction, direct immune
system stimulation, diversity of the C. acnes population, porphyrin production, mobile ge-
netics elements, and associated CRISPR/CAS loci to the production of SCFAs [156–162].
Many reviews on this topic are published, with the most recent being by Brüggemann [163].
Despite many years of research, the precise interdependence and choreography of pathogenic
events in acne remain unclear. The main challenge is to distinguish between health- and
disease-associated C. acnes strains. Multiple observational studies have been published
on this subject and came to slightly varying conclusions. However, most of these studies
overlap in the finding that Clade II strains are health-associated, while there is dispute on
the functional reasoning behind this [164]. Some studies suggest that Clade IA strains are
disease-associated [72]. However, this clade is also the most widespread in healthy skin. This
leads to the search for pathogenicity-defining biomarkers in the subpopulation of Clade IA.
Multiple biomarkers are suggested, such as mobile genetic elements, linoleic acid isomerase
activity, porphyrin production, or cell adhesion. The search for an efficient biomarker that
distinguishes acne-associated strains in Clade IA from health-associated strains is of partic-
ular interest as these strains have an evolutionary advantage over strains from Clade II, as
demonstrated by their wide distribution. Additionally, Clade IA strains produce high levels
of the antioxidant RoxP, which might be highly beneficial in protecting the host during the
normal aging process [165]. One aspect that is often undervalued is the interplay of different
C. acnes strains. A recent hypothesis stated that, instead of individual strains, the C. acnes strain
diversity is a distinguishing driver of health and disease [166]. A limited number of studies
have tested the potential use of probiotics (Lactobacillus, Bifidobacterium) to counteract the
adverse effects of antibiotic treatments and as an alternative treatment for acne vulgaris [117].
These theories are promising and are currently further investigated [167].
4.3. Gut Microbiome and Diet Implications in Acne Vulgaris
Already many decades ago, a connection between the gastrointestinal part and acne
vulgaris was suggested and followed by a first study in 1961 using oral Lactobacillus
supplements [66]. Later, this was substantiated by a trial showing a strong association of
diet and acne vulgaris [106]. Finally, in 2018, a study showed that acne vulgaris patients
actually have a distinct gut microbiome composition [168]. Acne patients have decreased
diversity of the gut microbiota with lower abundance of Firmicutes and increased levels of
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Bacteroides. Generally, Clostridium, Clostridiales, Lachnospiraceae, and Ruminococcaceae
were depleted in the acne cohort. While a distinct difference between the acne cohort and
the healthy controls was observed in this study, no correlation or distinctive biomarker was
found correlating with acne severity. Multiple studies have been performed looking at the
oral supplementation of probiotics in acne vulgaris [117,169,170]. The available results look
promising, but a high heterogeneity in the provided products as well as shortcomings in
the study design do not yet allow a final verdict on the efficacy of oral probiotic treatments
in acne vulgaris. HFD contains a large quantity of saturated fats and a high glycemic
load, which is strongly correlated with acne vulgaris [60,147]. The hypothetical cause is a
disturbed nutrient signaling with an uncontrolled stimulation of sterol regulatory element-
binding protein 1 (SREBP-1) and an increased synthesis of fatty acids and triglycerides
in the sebum, which stimulates the growth of C. acnes [171]. While the gastrointestinal
microbiome is only one of many factors contributing to acne, it has an undeniable impact
on the skin condition in acne vulgaris. Until now, the exact mechanism is unclear but it is
tempting to speculate a general influence of the gut microbiome on the immune system.
Figure 1. Inflammatory and microbial influences between the gut and skin for a healthy state (left) and a dysbiotic
state (right): The intestinal and epidermal barriers are connected through the systemic circulation (blood and lymph)
and are visualized here together in a simplistic manner. The dysbiotic state is characterized by an impaired gut barrier
(imbalance in gut microbiome, reduced mucus layer, reduced IgA secretion, barrier disruption, intestinal permeation into
the bloodstream, and gut inflammation) and an impaired skin barrier (imbalance in skin microbiome, reduced human
and microbial antimicrobial peptides (AMP) production, skin rashes/thickening/lesions, and skin inflammation). Gut
and skin dysbiosis are connected through an immune imbalance (Th2 skewing in this example), whereas crosstalk can
be bidirectional.
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5. Atopic Dermatitis (AD)
5.1. AD Pathophysiology
Atopic dermatitis is the most common inflammatory skin disease (7% of adults and
15% of children). It is an inflammatory skin disorder characterized by barrier dysfunction,
chronic inflammation, and microbial dysbiosis on skin [172]. AD is also influenced by host
genetics and environment [173]. The inflammation is driven by a Th2 cytokine pathway,
with the cytokines IL-4 and IL-13 playing an important role [174]. These play a central role
in type 2 inflammation, not only for atopic dermatitis but also for several other allergic
diseases. The IL-4 and IL-13 cytokines are involved in skin barrier disruption, decreased
skin lipid metabolism, and inhibited antimicrobial peptide synthesis [175]. These conditions
promote the growth and pathogenesis of Staphylococcus aureus [176]. The understanding
of this disease has improved a lot in recent years. There is nonetheless still a large unmet
need for long-term disease control.
Up to 30% of Caucasians have a mutation of the filaggrin gene, which codes for a
crucial protein regulating the epidermal homeostasis [177]. Filaggrin is affected in both
lesional and non-lesional skin.
Mild atopic dermatitis can be treated with skin moisturizers, topical corticosteroids,
antihistamines, immunosuppressants, and phototherapy [178]. Twenty to thirty percent
of patients have moderate-to-severe atopic dermatitis. For these patients, many biologics
are in development or have been developed targeting the Th2 axis, such as IL-4, IL-13,
IL-31, OX40, IL23p19, IL-5RA, and janus kinase (JAK)-inhibitors (which target several key
AD cytokines) [179,180]. So far, only dupilumab has been shown to improve moderate-to-
severe atopic dermatitis and subsequently approved [181].
5.2. Skin Microbiome in AD
Lesional skin in AD is commonly characterized by a low bacterial diversity [182].
The relative abundance of Staphylococcus aureus and Staphylococcus epidermidis is increased,
while a decrease in Cutibacterium, Corynebacterium, Streptococcus, Acinetobacter, Prevotella,
and Malassezia is found [80,83]. Specifically, S. aureus has long been associated with the
skin pathology [183]. S. aureus has been found in higher relative and absolute abundances
on lesional skin compared to nonlesional skin [184]. S. aureus was found more abundantly
on AD skin compared to healthy controls [80,81]. The relative abundance of S. aureus
is correlated with disease severity [82]. Colonization by S. aureus may play a critical
role in perpetuating skin inflammation through the development of Th2 cells induced by
peptidoglycan [185]. These are common cell components of S. aureus strains. The barrier
disruption as well as reduced levels of ceramide cause the peptidoglycan to penetrate
into the skin [185]. The peptidoglycan of S. aureus can induce human cathelicidin LL-37
and vascular endothelial growth factor (VEGF) expression in keratinocytes, with VEGF
production being amplified by subsequent IL-13 overproduction [186]. S. aureus and its
enterotoxins as such trigger inflammation through direct infection of the keratinocytes [187].
Due to the impaired barrier, AD lesions are also susceptible to viral infections, although the
occurence is rather rare. The most common is infection with herpes simplex virus (called
eczema herpeticum) [188]. Another recently described case is infection with coxsackie virus
(called eczema coxsackium) [189]. Atopic dermatitis is usually treated with topical agents,
including moisturizers, corticosteroids, calcineurin inhibitors, or antimicrobials [190]. The
mode of action is restoring the skin barrier, reducing inflammation, and reducing the
bacterial load. Bacteriotherapy has also been tested in the case of atopic dermatitis, through
application of coagulase-negative Staphylococcus spp. (for instance, S. epidermidis and S.
hominis). In a mouse model, S. hominis provided selected protection against S. aureus by
secreting lantibiotics and showed potential in producing AMPs [191].
5.3. Gut Microbiome and Diet Implications in AD
Studies have shown a gut dysbiosis association in patients with atopic dermatitis.
The gut microbiome of AD patients was enriched in Faecalibacterium prausnitzii, had more
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genes encoding for release of molecules that can damage the gut epithelium, and had
lower levels of butyrate and propionate, which possess anti-inflammatory properties [107].
Higher levels of Clostridium and Escherichia were found in the gut of atopic infants compared
to healthy controls [108–111]. Clostridium and Escherichia coli in the intestine can contribute
to an inflammatory state [110]. On the other hand, lower levels of Akkermansia, Bacteroidetes,
and Bifidobacterium were found in AD patients, compared to healthy controls [112,113].
Butyrate-producing bacteria (f.i. Coprococcus) were more abundant in healthy infants
or infants with mild AD, compared to infants with severe AD [192]. A likely effective
therapeutic option for AD involves the consumption of probiotics, for which a considerable
number of studies have been published [193]. In most of the studies Lactobacillus and
Bifidobacterium have been tested [194]. Studies have been conducted in children and adults
and during pregnancy, for which often contrasting efficacy results have been obtained [195].
Evidence from a meta-analysis supports the use of probiotics for the treatment of AD in
infants; however, the benefit likely results from primary prevention of atopic dermatitis,
as also concluded by the World Allergy Organization [114,196,197]. The prophylactic effect
of probiotics is likely due to its mediating role on the host immune system. Probiotics can
interact with dendritic cells, can balance Th1/Th2 immunity, and can enhance Treg activity,
as described in in vitro and in animal models [198,199]. These studies show the impact of
the gut microbiome (dysbiosis) on Th2-type immune response to allergens in the skin [200].
Diet has been implicated in atopic dermatitis and Th2-driven inflammations. A reduced
consumption of fruit, vegetables, and ω-3 fatty acids and increased consumption of ω-6
fatty acids have been linked to atopic dermatitis [201,202]. Epidemiologic studies have
demonstrated associations of atopic dermatitis (and asthma) with margarine, fish, ω-6
polyunsaturated fatty acid (PUFA), and ω-3 PUFA [202]. Further research is nonetheless
required to prove the conclusive effect of dietary manipulations on the reduction in atopic
disease (and asthma), as previous studies have failed to do so [202,203].
6. Psoriasis
6.1. Psoriasis Pathophysiology
Psoriasis is an immune-mediated inflammatory disease (IMID) and one of the most
prevalent chronic skin diseases (0.1–12%) in the world [204]. It is characterized by red,
scaly, and thickened skin lesions that can occur at any site of the body [205]. It is a
multifactorial disease with an intimate interplay between genetic susceptibility, lifestyle,
and environment [205–209]. Numerous comorbidities are reported, suggesting psoriasis
to be a systemic disease rather than just a skin disease [210,211]. Similarly, stress has
been reported to be an important trigger and crucial exacerbating factor [212,213]. It is
primarily considered a Th17 disease with a major role for IL-23/IL-17-mediated inflamma-
tion, where tumor necrosis factor (TNF) enhances the inflammatory feedback loop [214].
Consequently, moderate-to-severe psoriasis is treated with therapeutic antibodies, termed
biologics, that target these cytokines, including TNF, IL-17, IL-23, and IL-12/23. These
drugs have revolutionized the therapeutic landscape in related IMIDs as well, such as
hidradenitis suppurativa (HS), rheumatoid arthritis, and IBD (Crohn’s disease (CD) and
ulcerative colitis (UC)). Interestingly, psoriasis is also characterized by a type I interferon
(IFN) signature in lesional skin, including upregulated expression of IFN-stimulated re-
sponse element (IFN-ISRE) genes [215–217]. Since psoriasis has no clear cause, it is not
considered a classic autoimmune disease. Nonetheless, the AMP LL-37 is found complexed
with DNA in increased levels in lesional skin and is targeted by autoantibodies in the
arthritis subform of psoriasis [218]. However, the presence of specific cytokine profiles in
certain diseases associated with specific antimicrobial responses begs for the role of the
microbiome in a disease such as psoriasis, which for instance includes an antiviral response
(i.e., type I IFN).
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6.2. Skin Microbiome in Psoriasis
The psoriatic skin microbiome has been described in several studies [84–87], and is
mainly characterized by a relative higher abundance of Staphylococcus and Streptococcus
species. The various studies often show different outcomes: some studies report a decreased
microbial diversity, whereas others describe an increase in diversity. Yerushalmi et al.
performed a systematic review on microbial studies in psoriatic disease and reported
a general decrease in α-diversity: a higher and lower relative abundance of Firmicutes
and Actinobacteria, respectively, in comparison to healthy controls [88]. At the genus
level, the results are less consistent according to the systematic review: Corynebacterium,
Staphylococcus, and Streptococcus are reportedly more present in lesional skin, whereas
a decrease in Cutibacterium is observed [88]. This discrepancy supposedly stems from
the variety in study design (e.g., lesional skin versus nonlesional skin versus healthy
controls, body sites, and medication) and analytic methodology [219]. In psoriasis, a lower
abundance of S. epidermidis and C. acnes may enable increased colonization of S. aureus [87].
Indeed, S. aureus colonization has been found to stimulate Th17 polarization in mice,
suggesting that S. aureus triggers IL-17-mediated skin inflammation [87].
A clinical subform of psoriasis, called guttate psoriasis, is usually triggered by a
streptococcal throat infection and generally evolves into the vulgaris (plaque) form. People
with psoriasis vulgaris also report exacerbation of the disease severity following tonsillitis.
Psoriasis associated with tonsillitis may be controlled by tonsillectomy [220,221]. HLA-
C*06:02, a well-known psoriasis-associated single nucleotide polymorphism (SNP), has
been found to be associated with chronic and recurrent streptococcal tonsillitis [222].
The effect of anti-psoriasis treatments on the skin microbiome has been investigated
as well. Psoriasis patiens treated with narrowband UVB light therapy displayed reduced
presence of Firmicutes, Staphylococcus, Finegoldia, Anaerococcus, Peptoniphilus, Gardnerella,
Prevotella, and Clostridium spp. in lesions posttreatment [223]. Conventional and biological
systemic treatments (e.g., cyclosporin A, retinoic acids, fumarates, methotrexate, adali-
mumab, and ustekinumab) resulted in a change in the Actinobacteria to Firmicutes ratio,
with biologics having the greatest effect [224].
Characterization of the viral microbiome in psoriasis has not been studied as exten-
sively as its bacterial counterpart. Interestingly, the presence of a type I IFN signature
in psoriasis suggests an antiviral response. Triggers through viral infections have been
described, albeit evidence remains limited [225,226].
6.3. Gut Microbiome and Diet Implications in Psoriasis
People with psoriasis have an increased risk to develop intestinal immune disorders,
such as IBD, UC, and celiac disease [118,119,227]. The exact mechanism is not entirely
understood, and though many pro-inflammatory cytokines play similar roles in IMIDs,
the responses to treatments may differ entirely: the IL-17 blockade is beneficial in psoriasis
but rather harmful in IBD [228,229]. Integrity issues in psoriasis are found not only in the
skin but also at the intestinal level. Structural aberration in the form of decreased surface
in the jejunum was reported in psoriasis patients compared to healthy controls [230]. Other
aberrations have been reported as well, including intestinal infiltration of lymphocytes.
Lactose intolerance is significantly more present in psoriasis and is even associated with
psoriatic severity [227]. Loss of intestinal integrity has been reported in psoriasis based
on a 51Cr-labeled ethylenediaminetetraacetic acid (EDTA) absorption test [231] and more
recently through increased levels of barrier-related proteins such as claudin-3 and intestinal
fatty acid binding protein (I-FABP) in serum [232]. Higher levels of fecal calprotectin
were found, were correlated to disease severity [233], and were especially increased when
joint inflammation was involved [233]. Studies have shown the presence of ribosomal
DNA in the peripheral blood of psoriasis patients, including DNA from Streptococcus and
Staphylococcus spp. [234,235]. In mice, intestinal inflammation drove imiquimod-induced
psoriasis-like skin inflammation [116].
Microorganisms 2021, 9, 353 12 of 34
A number of studies investigated the gut microbiome of psoriasis patients, which
showed differences in β-diversity (Table 2). Two studies reported lower relative abun-
dance of Bacteroidetes and higher Firmicutes in psoriasis patients compared to healthy
controls [115]. The gut microbiome has also been investigated in response to anti-psoriasis
treatment: secukinumab, an IL-17 inhibitor, had a greater impact on the gut microbiome in
comparison to ustekinumab, an IL-12/23-p40 inhibitor. In detail, the relative abundance of
Proteobacteria, Pseudomonadaceae, Enterobacteriaceae, and Pseudomonadales increased
in response to secukinumab, whereas Bacteroidetes and Firmicutes declined [120]. These
findings suggest a link between psoriasis and the intestinal health.
Lifestyle has major implications in psoriasis: smoking and alcohol have been associ-
ated with the exacerbation of skin lesions and even suboptimal responses to treatments,
whereas obesity is an independent risk factor for the development of psoriasis [236]. A
healthy weight is associated with beneficial effects: HFDs are associated with the ex-
acerbation of psoriasis, whereas weight reduction had a positive outcome on psoriasis
severity [237–239]. A response to treatment may also be susceptible to dietary intake, as a
very low-calorie ketogenic diet has been shown to improve response in patients with a
psoriasis relapse [237,240]. Intermittent fasting according to the Ramadan regimen has also
been found to positively impact moderate-to-severe psoriasis [241]. Indeed, the intestinal
dysbiosis in patients with psoriasis has been the target for probiotics [242]. A mixture of
strains was tested in psoriasis and found to be beneficial, up to 6 months after intervention,
with fewer relapses in the group treated with the probiotic mixture [243]. Recently, an oral
derivative of a single strain of Prevotella histicola was tested for psoriasis. In the murine
imiquimod model, it was found to be effective, which was confirmed in a phase 1b trial in
humans, yet the results remain to be published [122,244].
7. Hidradenitis Suppurativa (HS)
7.1. HS Pathophysiology
Another chronic cutaneous IMID is hidradenitis suppurativa, with a global prevalence
of 0.3% [245]. HS is characterized by occlusion of the apocrine glands, though it is also
commonly known as acne inversa, as it occurs in the inverse areas such as the axillae,
inframammary regions, groin, and genital and perianal regions. It typically involves
recurring, draining, and inflamed lesions that are painful and disfiguring. The lesions
consist of chronic subcutaneous sinus tracts, cutaneous fistulae, or dermal-cutaneous scars.
Though its etiology remains incompletely understood, research reports a dysregulation of
inflammatory cytokines and occlusion of the follicles. TNF is considered a key cytokine,
orchestrating the inflammatory loop with VEGF, IL-8, and IL-1β, whilst skin biopsies show
an increased ratio of Th17 cells compared to Tregs [246,247]. The use of adalimumab, an anti-
TNF antagonist, was found to be effective in the treatment of HS and to normalize the
Th17/Treg population. It is a multifactorial disease, where lifestyle plays a significant role,
including exacerbating effects of smoking and obesity. It remains incompletely understood
what the exact underlying mechanism is, and therapeutic interventions, additionally to
anti-TNF, include laser-assisted hair removal and antibiotics, yet no cure exists.
7.2. Skin Microbiome in HS
HS lesions present with bacterial infections, which are clinically considered secondary.
However, the lesions exhibit a distinct cutaneous microbiome in lesional and nonlesional
HS skin in comparison to healthy controls. More specifically, anaerobic species were
found in lesions, e.g., Prevotella and Porphyromonas, whereas aerobic commensals were
reduced. Interestingly, the HS-microbiome may have clinical relevance as Fusobacterium and
Parvimonas spp. were found to correlate to disease severity [89]. In addition, Saccharomyces
cerevisiae yeast and one of its wall components, mannans, may also play a role in HS:
anti-Saccharomyces cerevisiae antibodies (ASCAs) have been found in HS-serum and to be
specifically present in comparison to psoriasis vulgaris and healthy controls, underlining
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its importance as a biomarker [90]. Assan et al. even reported a significant elevation in the
severe cases (Hurley III stage), suggestive for a prognostic marker for disease severity [90].
7.3. Gut Microbiome and Diet Implications in HS
The main link with the gut is based on the increased risk in developing CD and UC:
based on a systematic review, usually a two-fold odds ratio was found [248]. Moreover,
both diseases respond to anti-TNF treatment, suggesting similar inflammatory pathome-
chanisms. Especially the presence of perianal fistulae in CD is interesting, and molecular
research of HS and CD fistulae has found that CD161+ T lymphocytes are enriched in these
lesions, which can differentiate into pathogenic Th17 cells [249]. Interestingly, the presence
of ASCAs in HS can be linked to several intestinal disorders such as Crohn’s and celiac
disease, where ASCAs are prevalent as well. Positivity for ASCA suggests a systemic
response to the oligomannosidic epitopes of yeast. Such observations imply that systemic
tolerance to microbial antigens may be exhibited in tissue-specific manifestations, including
cutaneous (HS) and intestinal (Crohn’s and celiac disease) [250]. In HS, several lifestyle
factors such as smoking, alcohol, and obesity are considered exacerbating factors. Es-
pecially cessation of smoking has been associated with significant improvement in HS
lesions [251,252].
Based on the intimate link with Crohn’s disease, dietary interventions have been
suggested as clinical interventions for HS. However more importantly, obesity is also
a known independent risk factor for HS, and a weight loss of at least 15% has been
associated with diminished disease severity [253]. Imbalance in the gut microbiome has
been associated with diets high in fat, including an increment in Firmicutes and a reduction
in Bacteroidetes. How the bacterial HS-associated gut microbiome responds to low fat
diets remains to be elucidated. Avoidance of food containing or made with the yeast
S. cerevisiae has resulted in promising long-term results in HS, including a reduction in
inflammation and amelioration of clinical response to (surgical) treatments [254]. Though
other “avoidance” diets are suggested for the treatment of HS, randomized controlled trials
are lacking to provide solid evidence for HS [255].
8. Rosacea
8.1. Rosacea Pathophysiology
Rosacea is a chronic inflammatory dermatosis characterized by various skin lesions
predominantly on the face including erythema, papulopustules, telangiectasia, and/or
ophthalmic involvement that affects up to 15% of the Caucasion population with fair
sun-sensitive skin (skin phototypes I and II) [256–258]. Although the pathophysiology
of rosacea remains unclear, neurovascular dysregulation, impaired immunity, external
factors, and genetic inheritance are suggested to play important roles in the disease pro-
gression [92]. Rosacea patients retain a dysregulated innate immune system that causes an
abnormal inflammatory cytokine release and an AMP response. Cathelicidin expression
is significantly increased in the epidermis of rosacea affected skin compared to normal
skin [259,260]. In granular or cornified layers of normal skin, cathelicidin nis early absent
whereas its expression is greatly induced by wounding or infection [261]. LL-37 is the most
common ly found cathelicidin peptide in rosacea patients [260]. Toll-like receptor 2 (TLR2)
levels are increased in rosacea patients and stimulate KLK5 [262]. In addition, particular
cathelicidin types stimulate and control leukocyte chemotaxis, vasodilation, angiogenesis,
and the expression of extracellular matrix proteins [263–265]. Neurogenic inflammation
might also play an important role in the pathogenesis of rosacea. Various rosacea triggers,
including heat and dietary factors, might activate and upregulate the transient receptor
potential (TRP) ion channels of vanilloid type (TRPV), which are expressed by sensory
nerves as well as by keratinocytes [266]. The TRP channels might be targets for rosacea
patients, as they play a role in inflammation, pain perception, and vasoregulation [262,266].
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8.2. Skin Microbiome in Rosacea
The skin of rosacea patients regularly contains an overgrowth of commensal skin
microorganisms. Higher concentrations of Demodex folliculorum were detected, which
usually inhabit the sebaceous glands. The D. folliculorum mite density has been reported
to attain up to 10.8/cm2 in rosacea patients in comparison to 0.7/cm2 in controls [91].
TLR2 is activated by cell-membrane components of the Demodex mite, which triggers KLK5
activity [267]. The use of permethrin against D. folliculorum reduced the mite abundance;
however, the skin lesions did not recover [268]. For this reason, researchers proposed
bacteria as a causative agent for the inflammatory responses in rosacea, and the role of
Bacillus oleronius and Staphylococcus epidermidis have been investigated [262,267,269,270].
The study of Woo et al. analyzed the influence of oral antibiotics on the composition and
diversity of the skin microbiome in rosacea patients. Staphylococcus epidermidis, a skin
commensal, is the predominant species, followed by C. acnes. Rosacea severity increased
with age and the relative abundance of C. acnes decreased, whereas the relative abundance
of Snodgrassella alvi increased. Geobacillus and Gordonia were significantly associated with
rosacea severity [271]. The use of topical metronidazole (1% cream) did not alter the
skin microbiota composition [272]. Zaidi et al. described that oral doxycycline (100 mg
for 6 weeks) did not affect the α-diversity but demonstrated an increase in the relative
abundance of Weissella confusa [273]. In contrast, Woo et al. reported a decrease in W.
confusa [271]. Further studies are thus needed to assess the effect of oral antibiotics on the
skin microbiome composition.
8.3. Gut Microbiome and Diet Implications in Rosacea
A link between gut microbial dysbiosis and rosacea has been hypothesised, as there is
an increased risk of gastrointestinal disorders in rosacea patients [274]. Especially Helicobac-
ter pylori infection (HPI) has been associated with the disease [123]. The prevalence of small
intestinal bacterial overgrowth (SIBO) is increased in rosacea patients. The elimination of
SIBO resulted in a significant reduction in cutaneous lesions [124]. A population-based
cohort study with 50,000 Danish rosacea patients could identify a higher prevalence of
celiac disease, CD, UC, HPI, SIBO, and irritable bowel syndrome (IBS) among the rosacea
subjects compared to the control subjects [274,275]. However, comprehensive studies are
missing that describe the role of gut dysbiosis in rosacea. A recent Korean study found
a link between several enteral microbiota and rosacea in a group of 12 female subjects
with rosacea [125]. The abundance of enteral microbiota was similar between patients
with rosacea and rosacea-free controls yet differed in composition. A higher abundance of
Acidaminococcus and Megasphaera and a lower abundance of Peptococcaceae and Methanobre-
vibacter were reported [125]. The study of Chen et al. demonstrated a reduction in the
fecal microbial richness in rosacea patients as well as a distinct fecal microbial commu-
nity. The altered microbial composition might be due to sulfur metabolism, cobalamin,
and carbohydrate transport [276]. The microbiome might be a critical therapeutic target.
An important note is that there is a lot of interindividual variability in the human intesti-
nal microbiome composition. Several reasons may account for this variability, including
genetics, environmental exposure, hygiene, geography, ethnicity, etc. [277].
Rosacea exacerbations are frequently linked to dietary factors that can mainly be
categorised into heat-related, alcohol-related, capsaicin-related, and cinnamaldehyde-
related [278]. There are multiple proposed mechanisms of action (MOA); one of them is
through the activation of TRP channels [279]. A second MOAPlease define if appropriate.
is through the gut–skin connection [274].
9. Dandruff and Seborrheic Dermatitis
9.1. Dandruff and Seborrheic Dermatitis Pathophysiology
Dandruff is a skin condition that mainly affects the scalp, resulting in skin flaking and
pruritus. It occurs in 30–50% of the world’s population, with males generally more affected
than females [280,281]. Severe forms of dandruff include inflammation of the skin and
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are known as seborrheic dermatitis. Seborrheic dermatitis is a chronic and inflammatory
dermatosis with recurrent character, and its pathophysiology is very similar to that of
dandruff [282]. The exact causes of these conditions remain unknown. However, several
factors have been implicated in the progression of the skin conditions, including sebum
levels, immune response, stress, environmental and hormonal changes, and individual
sensitivity [283]. Moreover, seborrheic dermatitis has been linked and can be caused by
an inflammatory immune response to Malassezia spp. [284]. It is usually treated with
anti-dandruff shampoos, containing antibacterial and antifungal agents.
9.2. Skin Microbiome in Dandruff and Seborrheic Dermatitis
Dandruff and seborrheic dermatitis are generally associated with a fungal component.
Malassezia spp. are lipophilic and dominant fungi colonizing the human scalp and are the
most abundant yeast species of the skin mycobiome [280]. Malassezia restricta, Malassezia
furfur, and Malassezia globosa are the most abundant species of the Malassezia genus. An in-
flammatory reaction to excess Malassezia spp. growth on skin has been associated with
seborrheic dermatitis [93]. Malassezia spp. are thought to cause an overproduction of oleic
acid, which disturbs the stratum corneum cells and evokes an inflammatory response on
the scalp [93]. This results in irritating free fatty acids and other metabolites, which can
lead to more sebaceous secretions on the scalp, which in turn leads to an inflammatory
response that results in skin changes [285]. Dandruff and seborrheic dermatitis occur solely
on skin areas with high levels of sebum [93]. Preferencial sites are sebaceous gland-rich
areas such as the face, ears, scalp, and upper trunk. Patients with oily skin are prone
to developing seborrheic dermatitis [94]. Analysis of the M. globosa genome showed an
absence of fatty acid synthase, while many lipase and phospholipase genes/enzymes were
present and active on human scalp [93]. This explains the nature of this yeast to heavily
rely on external (sebaceous) fatty acids to survive. A bacterial impact was also suggested,
with an imbalance in Cutibacterium and Staphylococcus species [95,96].
9.3. Gut Microbiome and Diet Implications in Dandruff and Seborrheic Dermatitis
The link between gut dysbiosis and dandruff/seborrheic dermatitis has been con-
troversial. Some deviations have been detected in the intestinal mucosa of patients with
seborrheic dermatitis [286]. A clinical study on probiotics consumption (Lactobacillus para-
casei strain) found significant improvements in severity and symptoms of moderate to
severe dandruff compared to a placebo treatment [126]. However, the influence of the gut
microbiome composition on seborrheic dermatitis and dandruff remains to be elucidated.
Diet has been reported as having an important contribution in the production of
sebum. Dietary lipids, glucose intake, and acetate have been indicated as influencing
for sebaceous gland activity [287]. Sugar consumption is often higher in patients with
seborrheic dermatitis, compared to healthy control groups [288]. Caloric restrictions have
been linked to reduced sebum production [289]. Increased levels of vitamin A in the blood
has also been linked to a decreased sebum production [290]. Dandruff patients are often
advised to avoid sugar, animal fats, and greasy food products and instead consume more
vegetables, water-based fruits, seeds, fish, biotin, and vitamin B, although no conclusive
evidence has been found for such recommendations [291].
10. Alopecia
10.1. Alopecia Pathophysiology
Alopecia areata is a skin condition with a prevalence of 2% and is clinically char-
acterized by small areas of hair loss on the scalp and/or all over the body [292]. The
pathophysiology is still unclear but there is some strong evidence that autoimmune reac-
tions cause inflammations at the site of the hair follicle. Research indicates that different
cells of the innate and adaptive immune system are correlated to alopecia areata. Th cells,
cytotoxic T cells, natural killer cells, and DCs are present at the hair follicle during the
anagen (growth) phase of the hair. The autoimmune responses of these cells cause the
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production of cytokines such as IFN-γ and TNF-α, which leads to collapse of the hair
follicle [293]. The factors that cause this immune response remain unknown. However,
there is some evidence that genetic disposition, several environmental factors, and even
maybe the skin microbiome can have some influences on the disease as well [294].
10.2. Skin Microbiome in Alopecia
The scalp microbiome mainly consists of Corynebacteriaceae, Propionibacteriaceae,
and Staphylococcaceae [99]. A small fraction of the scalp microbiome also consists of
fungi, with Malassezia restricta being the most important one. These microorganisms have a
symbiotic relationship on healthy scalp, while dysbiosis can cause pathological conditions.
A higher abundance of pathogenic taxa in the hair follicle can lead to infections and can
contribute to a pro-inflammatory state on the scalp [295]. Analysis of the scalp microbiome
of patients with alopecia areata demonstrated an increase in C. acnes in combination with
a decrease in S. epidermidis [99]. A disbalance in Cutibacterium/Staphylococcus spp. can
potentially play a role in alopecia areata [99]. An increase in cytomegalovirus and Alternaria
fungi in alopecia areata has also been postulated [97,98]. Skin microbiome data on this
scalp condition remains nonetheless scarce.
10.3. Gut Microbiome and Diet Implications in Alopecia
An association between gut dysbiosis and alopecia areata has been considered. Genes
that are related to alopecia areata may also affect gut colonization with microorganisms that
induce a Th1 response, which leads to the production of IFN-γ, as IFN-γ signals through a
JAK/signal transducer and activator of transcription (STAT) signal pathway [293]. Induc-
tion of this pathway can cause abnormal growth of hair follicle cells and can even progress
into hair loss. Furthermore, dysbiosis of the gut microbiome provokes other diseases
through manipulation of the T cell activity near and distant to the site of induction [296]. A
case report revealed hair growth in two patients with alopecia areata who were treated with
a fecal microbiota transplant (FMT) [128]. This also supports the hypothesis of the potential
role of the gut microbiome in the pathophysiology of alopecia areata. Some gut bacterial
differences were identified in alopecia areata patients, without major differences [127].
Based on the limited studies found in literature, a clear association between gut dysbiosis
and alopecia areata has not yet been determined.
A nutrient deficiency can impact hair growth and structure. Metal deficiencies, such
as iron and zinc, can cause hair loss. Low serum ferritin and zinc are more prevalent
in patients with alopecia areata. Vitamin deficiencies can also result in hair loss. Niacin
and biotin deficiency are proven to cause alopecia areata. Vitamin D takes part in hair
follicle cycling and vitamin A activates hair follicle stem cells. [297]. These deficiencies are
linked to hair loss and/or alopecia areata; however, limited information is available on
the effect of supplement intake and its association with hair loss and alopecia areata [297].
Furthermore, some diet alterations might also benefit the hair growth of alopecia areata
patients [298]. A gluten-free diet stimulated the hair growth of patients suffering from
celiac disease [298]. People who followed a soya-based eastern diet have a decreased risk
for alopecia areata, less than 1% instead of a global +/−2% risk [293]. The Mediterranean
diet, rich in raw vegetables and fresh herbs, or a high protein diet is a potential treatment
for alopecia [298]. However, the effect of a food limitation as a treatment for alopecia areata
needs to be further explored.
11. Skin Cancer
11.1. Skin Cancer Pathophysiology
Skin cancer is a common malignancy and can be divided into two categories: invasive
melanoma, in which melanocytes divide uncontrollably, and non-melanoma skin cancers
(NMSCs). The latter covers tumors with keratinocytic origin such as basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC) [299]. There is a wide variety of risk factors
that may lead to melanoma and NMSCs, which includes constitutional predisposition,
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immunosuppressive status, and exposure to environmental risk factors such as ultravi-
olet radiation [300]. In addition, actinic keratosis and Bowen’s disease may also result
in SCC [301]. During the last decennia, immunology involving cutaneous components
was better understood by the immunosurveillance mechanisms and the immunoediting
framework. The immunogenicity of tumor cells changes by an altered expression of (tumor-
associated) antigens, such as reduced MHC-1 expression, resulting in the development of
malignancy [302].
11.2. Skin Microbiome in Skin Cancer
The impact of viruses and UV radiation on skin cancer has already been extensively
examined. Recently, a lower incidence of skin cancer was discovered in germ-free rats.
As a result, it is hypothesized that dysbiotic skin microbiota can result in the development
of several skin cancers. However, it remains unclear whether tumor cells or microbial
dysbiosis trigger progression [303]. A number of studies have explored the link between
several skin cancers and dysbiosis of the bacterial skin microbiome in inflammatory dis-
eases involving Th17, such as psoriasis and acne [103]. Moreover, SCC and actinic keratosis
have recently also been associated with an increase in certain strains of S. aureus in com-
bination with a decrease in skin commensals [100]. Cheng et al. associates the latter with
the development of BCC [101]. Additionally, melanoma samples showed increased levels
of Fusobacterium and Trueperella genera according to a recent study by Mrázek et al. [102].
Furthermore, an increase in Merkel cell polyomavirus (MCPyV), a virus thought to be
a persistent resident of the skin, can lead to Merkel cell carcinoma (MCC) [103]. On the
other hand, specific S. epidermidis strains were shown to selectively inhibit proliferation
of tumor cell lines as it protects the progression of UVB-induced skin papillomas in pre-
clinical models [304]. S. epidermidis produces 6-N-hydroxyaminopurin, which interferes
in Streptococcus synthesizing DNA polymerase without interfering primary keratinocyte
growth [303]. Protective reactive oxygen species (ROS) are reduced in actinic keratosis and
BCCs [165,305]. This shows that skin commensals, such as C. acnes and S. epidermidis, can
protect the host from UV-induced DNA damage. Furthermore, treatments with topical
probiotics are suggested to reduce the risk of skin cancer due to increased immune surveil-
lance and reduced chronic inflammation. In fact, topical probiotics may alter the tumor
microenvironment by changing the immune responses, which may lead to therapeutic
effects [103]. However, more research is still needed to fully understand the role of skin
microbiota in skin cancer.
11.3. Gut Microbiome and Diet Implications in Skin Cancer
Cancer patients are also frequently subjected to dysbiotic gut microbiota because of
therapies affecting the composition and immunity of these microbiota [306]. Although the
link between this dysbiosis and skin cancer in particular remains unclear, the link with
cancer in general has already been investigated to a limited extent. For example, colorec-
tal cancer (CRC) is associated with an increase in Bacteroides fragilis in murine models.
Additionally, an altered gut microbiome leads to an increased risk to develop CRC [129].
Moreover, Guo et al. discovered the link between Helicobacter pylori and an increased risk of
pancreatic cancer [130]. This may be a consequence of a disturbed gut microbiome, which
has been described in Helicobacter-associated diseases [131]. However, more research is
needed to investigate the correlation between gut dysbiosis and skin cancer. Finally, it is
uncertain whether tumor development is secondary to bacterial dysbiosis.
12. Wound Healing
12.1. Wound Pathophysiology
Cutaneous wound healing is a very complex and organized process and consists
of overlapping phases of acute healing [307]. Multiple cell types, primarily epidermal
keratinocytes, neutrophils, and macrophages, are involved and interact with residing
commensal microbiota. The latter one may colonize wounds and may stimulate wound
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healing by promoting the innate immune system. Subsequently, keratinocytes expand and
migrate, fibroblasts migrate and amass the extracellular matrix (ECM), and angiogenesis
ensues during the proliferation phase. In the remodelling phase, the ECM restores, scar
formation appears, and the epidermal skin barrier recovers [307]. When one of these phases
is hampered, the epithelial barrier will not heal properly and a wound becomes chronic.
Impaired wound healing is a major challenge for the health care system, as it affects
roughly 1% to 2 % of the population in developed countries [308,309]. The prevalence of
chronic wounds is higher in older people with underlying pathologies including diabetes
mellitus, vascular disease, and obesity [310]. The cellular programs restoring the skin
barrier do not function properly in chronic wounds [307,311,312]. Impaired wound healing
is characterized by accelerated keratinocyte proliferation, impaired migration, and fibrosis.
In addition, several processes such as angiogenesis, ECM remodelling, and induction
of stem cells are hindered. Chronic wounds were also continuously inflamed, as was
demonstrated by several studies [307,313–317]. However, the underlying cellular and
molecular mechanisms of impaired wound healing are not yet fully understood. Especially
the role of skin microbiome in impaired wound healing and the application of antimicrobial
products are still questioned [312].
12.2. Wound Skin Microbiome
Wounds provide an ideal opportunity for microbiota to obtain access to underlying
tissues and to meet the ideal conditions to colonize and grow [318,319]. Commensal mi-
crobiota are thought to be beneficial for the wound healing process. They are essential
for regulating the skin innate immune system, as they stimulate the production of antimi-
crobial molecules that provide protection against intracellular pathogens [318,320,321].
Keratinocytes are effective killers of intracellular bacteria in a perforin-2 (P-2)-dependent
manner [322]. Skin commensal bacteria, such as S. epidermidis, are able to regulate the
gamma delta (γδ) T cells and to induce the P-2 expression. Intracellular S. aureus were
destroyed by skin cells as a result of the increased P-2 expression, which was induced
by S. epidermidis [323]. In addition, certain S. epidermidis strains produce trace amines
that accelerate wound healing in mice [324]. Disruption of the normal skin microbiota
may contribute to impaired wound closure and the chronic wound pathology. Wound
microbiome studies reveal that 21 bacterial families account for the majority of microbiota
that colonize chronic wounds [325,326]. Methicillin-resistant S. aureus (MRSA) is one of
the most common pathogens to colonize wounds [104]. Similarly, biofilm forming bacte-
ria have been associated with delayed wound healing [326]. Probiotics, like Lactobacillus
as well as fermented products have been tested to counteract the detrimental effects of
wound colonizing microbes [104,105].
12.3. Gut Microbiome and Diet Implications in Wound Healing
Alterations in the commensal skin microbiome may contribute to the formation of
chronic wounds. Recent research in animal models suggests that probiotics may hinder and
cure non-healing wounds. Kefir extracts in topical gels have improved the epithelialization
and the collagen generation in burn injuries in rats compared to controls that were treated
with silver sulfadiazine [327]. The administration of oral probiotics to ultraviolet injured
mice modulated the quantity of immune cells in the skin as well as the IL-10 levels, illustrat-
ing the immunomodulating potential of probiotics in skin tissues [46]. Supplementation of
lactic acid bacteria in drinking water stimulated the healing process in mice compared to
controls. In addition, the probiotic strain Lactobacillus reuteri improved wound healing by
stimulating oxytocin, which induced the CD4 + Foxp3 + CD25 + Treg lymphocytes that
convey the wound healing capacity [328]. These data support the notion that Tregs have
the potential to modulate the immune system beyond the gut.
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13. Conclusions
The skin diseases as discussed in this manuscript result from a complex interaction
between genetic susceptibility, lifestyle, and the immune system. More specifically, the lat-
ter is in constant orchestration with the nervous and endocrine systems. These interactions
allow microbiota to play a key role, especially in organs such as the skin and gut that
are richly perfused with immunoregulators and microbiota. Additionally, observations
such as the prevention of AD through probiotics and the increased prevalence of intesti-
nal comorbidities in chronic skin diseases suggest that skin diseases can be linked to the
gastrointestinal system. The main hypothesis relies on the gut health, which is directed
by dietary factors, mediated through the intestinal microbiome and the immune system,
leading to systemic effects, including skin health. The integrity of the intestinal barrier
plays a key role, which if compromised, leads to a “leaky gut”—an impaired intestinal
barrier. However, its existence remains heavily debated.
This intestinal microbial dysbiosis poses an interesting field of investigation and
applications. Pre- and probiotics aimed at the intestinal microbiome may be used for
targeting skin health [45]. Probiotic-fed mice with Lactobacillus reuteri demonstrated a
shinier and thicker fur mediated through IL-10 and, upon the addition of purified Foxp3+
T cells, also improved the integumentary system [329]. In a placebo controlled human
study, healthy volunteers obtained a lower transepidermal water loss and lower skin
sensitivity when consuming probiotics compared to the placebo group [330]. Interestingly,
consumption of probiotics or live bacteria that are beneficial for the gastrointestinal system
has potential to prevent and manage various skin diseases, such as acne vulgaris, atopic
dermatitis, and psoriasis [331–336]. Similar beneficial health effects have been determined
by consuming prebiotics and synbiotics [337,338]. However, specific diets such as caloric
restriction and low fat diets have also been associated with improved intestinal epithelial
barrier or with cutaneous improvements, including acne vulgaris, AD, psoriasis, wound
healing, skin cancer, and even skin aging [339,340].
The attractiveness of targeting the gut microbiome through oral delivery seems in-
versely correlated with the complexity of targeting the gut–skin axis: modulation of the
intestinal microbiome may lead to systemic effects, including the skin and other organs.
Properly designed clinical trials are needed to assess the effectiveness of microbiome-
targeted treatments. Recent advances in short-read and long-read sequencing technologies
permit detailed understanding in gut and skin microbial mediators. These technologies
should be accompanied by biomarker analyses (f.i. IgA, calprotectin, and immune mea-
surements) to identify the interplay between the microbiome and the gut barrier integrity.
Though the microbiome also includes viral microbiota, little evidence is available on
how viruses impact skin diseases and the intestinal health. The upcoming whole genome
sequencing should facilitate our knowledge on the role of viruses in the gut–skin axis.
Skin health outcomes need to be defined in order to determine the impact. Skin tape
stripping, which has recently been introduced for protein and mRNA quantification, will
enable noninvasive sampling, which is less burdensome for the study subjects. However,
one should take into account that skin tape stripping only reveals limited information in
comparison to skin biopsies.
Lastly, the study protocols need to take this complexity into account: the quality
of recording dietary habits is crucial and relies on the chosen method, such as patient-
reported outcome measures (e.g., a food frequency questionnaire versus digital apps
for calorie counting and food databases). Moreover, the moment of sampling should
be carefully considered: study subjects may have fasted at the moment of sampling by
skipping breakfasts versus those who did not. Moreover, the impact of the circadian
rhythm needs to be incorporated into future clinical trials. The current literature lacks
studies reporting on the impact of the circadian rhythm of nutrition uptake. The study
of Parkar et al. reviewed current evidence that demonstrated the effect of altered sleep
and eating patterns that may disrupt the host circadian system and that affect the gut
microbiome. They concluded that a distortion of microbiome rhythms might at least
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partly be responsible for an increased risk of obesity and metabolic syndrome linked with
insufficient sleep and circadian misalignment [341]. In addition to our own circadian
rhythm, the microbiota has also been described to exhibit an internal clock regulated
through microbial metabolites [342–344]. Presumably, certain nutritional components are
better metabolized at certain time points during the day. Indeed, high caloric intake during
evening hours has been associated with weight gain, whereas the same caloric intake
during morning hours results in weight maintenance [345].
In conclusion, the gut–skin axis, with a central role for our microbiota, poses an
exciting field of research, with promising therapeutic and cosmetic applications. Dissecting
the interactions between the microbiome and the hosting tissues will lead to a better
understanding of health and disease and will create novel opportunities. The need for
well-designed trials is primordial and will require multidisciplinary teams to work together,
reflecting the cooperation between our own bodies and microbiota.
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